SUBSCRIBE
SUBSCRIBE
News   FDA

Orexo AB’s Abstral(TM) Receives Two Further Large EU Market Approvals in France and Spain

March 2, 2009 | 
1 min read
STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo (STO:ORX), announces that AbstralTM has received Marketing Authorisation from the French and Spanish regulatory authorities for the treatment of breakthrough cancer pain.
FDA Approvals Europe
MORE ON THIS TOPIC
Human brain with abstract visualization of neuron activity
Alzheimer’s disease
Lilly Gets FDA Label Update for Alzheimer’s Drug To Mitigate Safety Concerns
July 9, 2025
 · 
2 min read
 · 
Annalee Armstrong
Podcast
Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More
July 9, 2025
 · 
1 min read
 · 
Heather McKenzie
FDA signage at its headquarters in Maryland
ALS
ALS Community Petitions FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival Data
July 8, 2025
 · 
3 min read
 · 
Heather McKenzie
Success to win in business competition, overcome obstacles or motivation to solve problem and lead company achievement concept, confident businessman leader jump high over 3 hurdles to be winner.
Approvals
KalVista Wins OK for First On-Demand Hereditary Angioedema Pill
July 7, 2025
 · 
2 min read
 · 
Tristan Manalac